What is Wuhan Hiteck Biological Pharma Co Revenue per Share?
Wuhan Hiteck Biological Pharma Co's revenue per share for the
three
months ended in Mar. 2025 was ¥1.24.
Wuhan Hiteck Biological Pharma Co's revenue per share for the trailing twelve months (TTM) ended in Mar. 2025 was ¥5.18.
Warning Sign:
Wuhan Hiteck Biological Pharma Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Wuhan Hiteck Biological Pharma Co was 23.20% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -5.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -3.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -6.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Wuhan Hiteck Biological Pharma Co's Revenue per Share or its related term are showing as below:
SZSE:300683'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.7 Med: -3.5 Max: 21.6
Current: -5
During the past 12 years, Wuhan Hiteck Biological Pharma Co's highest 3-Year average Revenue Per Share Growth Rate was 21.60% per year. The lowest was -16.70% per year. And the median was -3.50% per year.
SZSE:300683's 3-Year Revenue Growth Rate is ranked worse than 76.52% of 907
companies
in the Drug Manufacturers industry
Industry Median: 4.4
vs SZSE:300683: -5.00
Wuhan Hiteck Biological Pharma Co Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Wuhan Hiteck Biological Pharma Co Revenue per Share Chart
Competitive Comparison of Wuhan Hiteck Biological Pharma Co's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Hiteck Biological Pharma Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Hiteck Biological Pharma Co's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wuhan Hiteck Biological Pharma Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Wuhan Hiteck Biological Pharma Co's PS Ratio falls into.
Wuhan Hiteck Biological Pharma Co Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Hiteck Biological Pharma Co (SZSE:300683) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Wuhan Hiteck Biological Pharma Co Revenue per Share Related Terms
Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Wuhan Hiteck Biological Pharma Co Business Description
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300683 has been successfully added to your 